Shelbi Atrash, MD
Hematology & Oncology · Charlotte, NCNPI 1417105941
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $954,005 of the $994,330 with a category attached, or 95.9%. Pfizer accounts for 86.3% of it on its own, with 21 other manufacturers making up the rest. Among hematology & oncology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 194 payments — averaging $5125.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$858K
- Johnson & Johnson$49K
- GSK$34K
- Takeda Pharmaceuticals U.S.A., Inc.$18K
- Sanofi$18K
- Janssen Scientific Affairs, LLC$5K
- plus $12K from 16 others
Across 142 payments — averaging $59,975 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$4M
- Takeda Pharmaceuticals U.S.A., Inc.$1.3M
- GSK$1.1M
- Bristol Myers Squibb$1.1M
- Janssen Research & Development, LLC$683K
- Karyopharm Therapeutics Inc.$254K
- plus $85K from 4 others
What the payments were for
- Consulting fees$954,00596%
- Speaking & faculty fees$27,2173%
- Travel & lodging$7,3981%
- Food & beverage$5,6521%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 40 | $857,663 |
| Johnson & Johnson | 58 | $48,970 |
| GSK | 9 | $34,309 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $18,295 |
| Sanofi | 28 | $18,052 |
| Janssen Scientific Affairs, LLC | 6 | $4,630 |
| E.r. Squibb & Sons, L.L.C. | 5 | $4,058 |
| Bristol Myers Squibb | 13 | $3,816 |
| Karyopharm Therapeutics Inc. | 8 | $1,900 |
| Janssen Global Services, LLC | 1 | $1,430 |
| Menarini Silicon Biosystems, Inc. | 1 | $214 |
| AstraZeneca | 2 | $195 |
| Seagen Inc. | 1 | $114 |
| Regeneron Healthcare Solutions, Inc. | 1 | $114 |
| AbbVie | 1 | $107 |
| Merck | 1 | $106 |
| Amgen | 1 | $102 |
| Astrazeneca UK Limited | 1 | $96 |
| Janssen Research & Development, LLC | 2 | $80 |
| F. Hoffmann-la Roche AG | 1 | $49 |
| Legend Biotech USA Inc. | 1 | $18 |
| Secura Bio, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$994,330 in reported general payments places this provider in the 95th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $15,930 |
| TwinrixHepatitis A And B Vaccine/Pf | 15 | $2,025 |
| Acyclovir | 147 | $1,882 |
| PentacelDipht,pert(A),tet-Polio/Hib/Pf | 15 | $1,843 |
| Dexamethasone | 26 | $450 |
| Oxycodone Hcl | 32 | $447 |
| Gabapentin | 30 | $393 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 18 | $174 |
| Ondansetron Hcl | 30 | $161 |
| Tramadol Hcl | 15 | $118 |
| Omeprazole | 15 | $115 |
| Trazodone Hcl | 13 | $76 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $857,663 | $15,93020 claims |
| GSKTwinrix | $34,309 | $2,02515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 358 hematology & oncology providers in North Carolina.
Other hematology & oncology in Charlotte
- Nasfat ShehadehCharlotte$68K
- Jennifer AtlasCharlotte$59K
- Joseph MerrimanCharlotte$50K
- Justin FavaroCharlotte$33K
- Amit MehtaCary$4.3M
- Michael MorseDurham$2.6M
- Phillip FebboDurham$749K
- Angela AlistarWinston Salem$509K
- Ravi PaluriWinston Salem$314K
- Matthew McKinneyDurham$277K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.